Economic Aspects Of Biotechnology

Both macro- and microeconomic aspects of biotechnology are discussed in this book for biologists studying microbiology, biochemistry and genetics. It explains economics and accounting procedures from first principles and assumes no prior knowledge of these areas. The author works on developing new biotechnological projects. He draws extensively on his own experience and brings together the factors which determine commercial reasoning towards biotechnology in areas such as markets, project selection, costing and capital investment. His subjects include market analysis, fermentation, enzyme technology, genetic engineering and many others; they are all tied together by a common framework of industrial and technological development.

Adding yet another dimension to the debate on biotechnology that already encompasses technology and ethics, four Canadian economists and a Welsh scholar of management look at how the field may bring about significant economic upheavals, focusing on the agrifood industrial complex and specifically avoiding any consideration of human medical and pharmaceutical aspects. The topics include intellectual property, the environment, consumer issues, who gets biotechnology rents, and international issues. c. Book News Inc.

Describes the economic, scientific, and social factors that will influence the future of biotechnology in agriculture. Shows that both private and public sector R&D are contributing significantly to the development of biotechnologies. A review of 23 published studies on the subject.

The principal message of this book is that thermodynamics and statistical mechanics will benefit from replacing the unfortunate, misleading and mysterious term "entropy" with a more familiar, meaningful and appropriate term such as information, missing information or uncertainty. This replacement would facilitate the interpretation of the "driving force" of many processes in terms of informational changes and dispel the mystery that has always enshrouded entropy. It has been 140 years since Clausius coined the term "entropy"; almost 50 years since Shannon developed the mathematical theory of "information"--Subsequently renamed "entropy." In this book, the author advocates replacing "entropy" by "information," a term that has become widely used in many branches of science. The author also takes a new and bold approach to thermodynamics and statistical mechanics. Information is used not only as a tool for predicting distributions but as the fundamental cornerstone concept of thermodynamics, held until now by the term "entropy." The topics covered include the fundamentals of probability and information theory; the general concept of information as well as the particular concept of information as applied in thermodynamics; the re-derivation of the Sackur-Tetrode equation for the entropy of an ideal gas from purely informational arguments; the fundamental formalism of statistical mechanics; and many examples of simple processes the "driving force" for which is analyzed in terms of information.

Within the context of the Convention on Biological Diversity (CBD), the Cartagena Protocol on Biosafety (CPB) was established as an implementing agreement. The CPB is an international agreement establishing the rights of recipient countries to be notified of and to approve or reject the domestic import and/or production of living modified organisms (LMOs). Decisions regarding import/production are to be on the basis of a biosafety assessment. Article 26.1 of the CPB allows for the (optional) inclusion of socio-economic considerations (SECs) into that biosafety assessment process. This book compiles expert assessments of the issues relevant to SEC assessment of LMOs and fundamental for decisions regarding whether to undertake such assessments at all. It includes an overview of the inclusion of SEC assessment in the regulation of LMOs that looks at the rationale for the inclusion of SECs, in the context of the existing science-based risk assessment systems. This book reviews the various factors that can and have been suggested for inclusion in SEC assessment, and provides a meaningful dialogue about the contrasts, benefits and tradeoffs that are, and will, be created by the potential move to the inclusion of SECs in the regulation of LMOs, making it of interest to both academics and policy-makers.

The tremendous progress in biology over the last half century - from Watson and Crick's elucidation of the structure of DNA to today's astonishing, rapid progress in the field of synthetic biology - has positioned us for significant innovation in chemical production. New bio-based chemicals, improved public health through improved drugs and diagnostics, and biofuels that reduce our dependency on oil are all results of research and innovation in the biological sciences. In the past decade, we have witnessed major advances made possible by biotechnology in areas such as rapid, low-cost DNA sequencing, metabolic engineering, and high-throughput screening. The manufacturing of chemicals using biological synthesis and engineering could expand even faster. A proactive strategy - implemented through the development of a technical roadmap similar to those that enabled sustained growth in the semiconductor industry and our explorations of space - is needed if we are to realize the widespread benefits of accelerating the industrialization of biology. Industrialization of Biology presents such a roadmap to achieve key technical milestones for chemical manufacturing through biological routes. This report examines the technical, economic, and societal factors that limit the adoption of bioprocessing in the chemical industry today and which, if surmounted, would markedly accelerate the advanced manufacturing of chemicals via industrial biotechnology. Working at the interface of synthetic chemistry, metabolic engineering, molecular biology, and synthetic biology, Industrialization of Biology identifies key technical goals for next-generation chemical manufacturing, then identifies the gaps in knowledge, tools, techniques, and systems required to meet those goals, and targets and timelines for achieving them. This report also considers the skills necessary to accomplish the roadmap goals, and what training opportunities are required to produce the cadre of skilled scientists and engineers needed.

Addresses the fact that ag. biotech. (AB) has been advancing very rapidly, and while it presents many promises, it also poses many questions. Many dimensions to AB need to be considered to adequately inform public policy. Policy is made more difficult by the fact that AB encompasses many policy issues addressed in very different ways. The report identifies several key areas -- ag. research policy, industry structure, production and marketing, consumer issues, and future world food demand -- where AB is dramatically affecting the public policy agenda. Focuses on the economic aspects of these issues and addresses some current and timely issues as well as longer term issues. Charts and tables.